-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VKBc7wofxYYxmwnjiaNo0NUjqlEaQZMEqV0q9yNstzCed2n7PdGPgzTTpol8tshi
 7+ecFGHbWKS0kMwPMSs0nw==

<SEC-DOCUMENT>0001279569-09-000155.txt : 20090205
<SEC-HEADER>0001279569-09-000155.hdr.sgml : 20090205
<ACCEPTANCE-DATETIME>20090205130423
ACCESSION NUMBER:		0001279569-09-000155
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090205
FILED AS OF DATE:		20090205
DATE AS OF CHANGE:		20090205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09570989

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>oncolytics6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
  <head>
    <title>oncolytics6k.htm</title>
<!-- Licensed to: CNW Group-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--
    PAGEBREAK -->
&#160;

    <div style="FONT-FAMILY: 'Times New Roman',Times,serif">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      <div style="FONT-SIZE: 14pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SECURITIES AND<font size="+0" style="FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"> EXCHANGE</font>
COMMISSION</font><br></font></font></font></font><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Washington, D.C.
20549</font></div>
      <div style="FONT-SIZE: 12pt" align="center">&#160;</div>
      <div style="FONT-SIZE: 18pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">F<font size="+0" style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">orm</font>
6-K</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font size="+0">Pursuant to Rule</font>&#160;13a-16 or 15d-16<br>of the Securities
Exchange Act of 1934</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center">For the month of&#160;February 2009
</div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center">Commission File Number 000-31062
</div>
      <div>&#160;</div>
      <center>
        <div style="FONT-SIZE: 24pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Onc<font size="+0" style="FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">oly</font>tics
Biotech Inc.</font></div>
        <hr style="COLOR: black" align="center" noshade size="1" width="45%">
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-STYLE: italic">(Translation of registrant&#8217;s name
into English)</font></div>
        <div style="FONT-SIZE: 10pt" align="center">&#160;</div>
      </center>
      <center>
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington
Crescent NW<br>Calgary, Alberta, Canada T2N 1X7</font></div>
        <hr style="COLOR: black" align="center" noshade size="1" width="45%">
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-STYLE: italic">(Address of principal executive
offices)</font></div>
        <div style="FONT-SIZE: 10pt" align="center">&#160;</div>
      </center>
      <div style="FONT-SIZE: 10pt">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&#160;20-F or Form&#160;40-F. </div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="49%">&#160;</td>
                <td width="2%">&#160;</td>
                <td width="49%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Form&#160;20-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">&#254;</font></div>
                </td>
                <td>&#160;</td>
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Form&#160;40-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
                </td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt">&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark if the registrant is
submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T
Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security holders.
</div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark if the registrant is
submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T
Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR. </div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&#160;12g3-2(b) under the
Securities Exchange Act of 1934. </div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="49%">&#160;</td>
                <td width="2%">&#160;</td>
                <td width="49%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Yes&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
                </td>
                <td>&#160;</td>
                <td valign="top">
                  <div style="TEXT-ALIGN: center">No&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">&#254;</font></div>
                </td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt">&#160;</div>
      <div style="FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number
assigned to the registrant in connection with
Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
      <div>&#160;</div>
      <div>
      </div>
      <div>&#160;</div>
      <hr style="MARGIN-TOP: -2px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="4">
      <div style="FONT-SIZE: 10pt">
      </div>
      <div>&#160;</div>
    </div><!-- PAGEBREAK -->

    <div>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div align="left">&#160;</div>
    <div>
    </div>
    <div>
    </div>
    <div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr>
                      <td align="left" valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">NUMBER</font></div>
                      </td>
                      <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="68%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="68%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="6%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
                      </td>
                      <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="68%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">News Release Dated
      <font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">February 5,
      2009 -</font></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Media
      Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North
      America</font></font></font></font></font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="FONT-FAMILY: 'Times New Roman',Times,serif">
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized. </div>
      <div>&#160;</div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="50%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="47%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" colspan="3" valign="top"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Oncolytics Biotech
      Inc.</font><br>(Registrant)</td>
              </tr>
              <tr>
                <td>&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" valign="top">&#160;</td>
              </tr>
              <tr>
                <td>&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">Date:&#160;&#160;February 5, 2009 </td>
                <td>&#160;</td>
                <td align="left" valign="top">By:</td>
                <td>&#160;</td>
                <td align="left" valign="top">/s/&#160;&#160;Doug Ball

                  <hr style="COLOR: black" align="left" noshade size="1" width="60%">      Doug Ball<br>Chief Financial Officer</td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt" align="center">
      </div>
      <div>&#160;</div>
    </div><!-- PAGEBREAK -->
</body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED FEBRUARY 5, 2009
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: CNW Group-->
<!-- Document Created using EDGARizer 4.0.7.0 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <pre>&#160;</pre>
    <pre>Exhibit 99.1</pre>
    <pre>News release via Canada NewsWire, Toronto 416-863-9350

	    Attention Business Editors:
	    Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering
	    North America

	    CALGARY, Feb. 5 /CNW/ - Dr. Brad Thompson, President and CEO of
Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate
overview of the Company at the 7th Annual BioPartnering North America
Conference on Monday, February 9, 2009 at 4:30 p.m. PST. The event will be
held at the Westin Bayshore Resort in Vancouver, B.C. from February 8-10,
2009.

	    About BioPartnering North America

	    Now in its seventh year, BioPartnering North America (BPN) offers
excellent partnering opportunities for lifescience innovators and investors.
Hosted by LifeSciences British Columbia, BIOTECanada, and BioAlberta, BPN
annually attracts senior business development executives from around the
globe. BPN offers a targeted approach to the best lifescience partnering
opportunities.

	    About Oncolytics Biotech Inc.

	    Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of Phase I/II and Phase II human trials
using REOLYSIN(R), its proprietary formulation of the human reovirus, alone
and in combination with radiation or chemotherapy. For further information
about Oncolytics, please visit www.oncolyticsbiotech.com

	    The presentation time is subject to change. This release and the
presentation related thereto contain forward-looking statements which involve
known and unknown risks, delays, uncertainties and other factors not under the
Company's control and which may cause actual results, performance or
achievements of the Company to be materially different from the results,
performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as
a cancer treatment, the success and timely completion of clinical studies and
trials, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process. Investors
should consult the Company's quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements, except
as required by applicable laws.

	    %SEDAR: 00013081E          %CIK: 0001129928

	    /For further information: For Canada: Oncolytics Biotech Inc., Cathy
Ward, 210, 1167 Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403)
670-7377, Fax: (403) 283-0858, cathy.ward(at)oncolytics.ca; For Canada: The
Equicom Group, Nick Hurst, 325, 300 5th Ave. SW, Calgary, Alberta, T2P 3C4,
Tel: (403) 538-4845, Fax: (403) 237-6916, nhurst(at)equicomgroup.com; For United
States: The Investor Relations Group, Erika Moran, 11 Stone St, 3rd Floor, New
York, NY, 10004, Tel: (212) 825-3210, Fax: (212) 825-3229,
emoran(at)investorrelationsgroup.com/
	    (ONC. ONCY)

CO:  Oncolytics Biotech Inc.

CNW 12:03e 05-FEB-09

</pre>
  </body>
</html>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
